REPAIR Impact Fund makes two investments after US/Canadian investment round, totaling USD 10 million. The Fund has now invested a total of USD 30 million in six companies. Copenhagen, Denmark, … Continue reading “Novo Holdings REPAIR Impact Fund invests USD 10 million in Curza and Spero”
Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate Date: July 19, 2019 | author: Forendo Pharma Forendo Pharma, a clinical stage drug development company focusing on novel treatments in … Continue reading “Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate”
14 July 2019 at 19:00 CET – Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment – – Gilead Gains Access to Galapagos’ Differentiated Drug Discovery Platform and Current … Continue reading “Gilead and Galapagos Enter Into Transformative Research and Development Collaboration”
Würzburg, Germany – July 11, 2019: vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), today announced the successful completion of a €9.5 million … Continue reading “vasopharm Closes €9.5 million Financing Round”
08 July 2019, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker as VP Immunology to the company’s management team. … Continue reading “NeoPhore appoints Dr Matthew Baker as VP Immunology”
27 June 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum … Continue reading “STORM Therapeutics appoints Dr John Haurum to the Board of Directors”
Life sciences focused fund has executed three investments to date Luxembourg-Strassen, June 25, 2019 – Vesalius Biocapital III (‘Vesalius’), the specialist life sciences venture capital investor, announces the final close of … Continue reading “Vesalius Biocapital III Announces Final Close of EUR 120 million Fund”
Nina Church joins as Executive Director of Global Clinical Development and Nancy Herje as Senior Director of Clinical Operations LONDON, June 25, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: … Continue reading “Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine”
First European Phase 3 study “FM57” on track to deliver headline data by the end of 2019 Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Patient recruitment completed for MED2005 Phase 3 study”
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore Jun 10, 2019 Deal valued at a total … Continue reading “Calliditas Therapeutics Licensing News”
Amsterdam, The Netherlands, June 6, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has closed … Continue reading “Kiadis Pharma completes acquisition of CytoSen Therapeutics, Inc.”
Ensifentrine delivery via MDI inhalers could dramatically expand clinical utility and commercial opportunity LONDON, June 04, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a … Continue reading “Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD”
LOS ANGELES, CA, May 30, 2019 – ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it is scheduled to present at the following investor and scientific conferences in May … Continue reading “ImaginAb to Present at Upcoming Investor and Scientific Conferences in May and June 2019”
New collaboration between Neuraxpharm and Bened Biomedical expands portfolio of Consumer Healthcare products Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) … Continue reading “Neuraxpharm launches first probiotic product PS128™”
22.MAY 2019 AT 18:00:00 CET Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an … Continue reading “Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies”
Amsterdam, The Netherlands, May 22, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted … Continue reading “Kiadis Submits Response to the European Medicines Agency’s Day 180 Second List of Outstanding Issues”
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces its unaudited interim results for the six months ended 31 March 2019. Highlights Commercial and Operational … Continue reading “IXICO plc – Half Yearly Report to 31 March 2019”
TURKU, Finland, May 21, 2019 /PRNewswire/ — DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family … Continue reading “DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables”
Secure supply and first vial presentation of a pivotal drug for acute promyelocytic leukaemia FARNBOROUGH, England, May 20, 2019: Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with … Continue reading “Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com